TrialCancer chemotherapy and pharmacology2022

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.

Wenyuan Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.